Ci 0.

Thirteen trials and 2392 patients or episodes were included. Empirical antibiotics antiGP were tested at baseline in eleven studies and persistent fever in two studies. Treatment was antiGP glycopeptide in nine trials. Seven studies were evaluated in the overall mortality and comparisons no significant differences between the comparator arms were seen, RR 0. 82 (95% CI 0. To 56. 1 20, 852 patients). Ten trials assessed failure including changes, failures, and six assessed overall failure, ignoring treatment modifications. The failure of the changes was significantly reduced, RR 0. 76 (95% CI 0. 68 to 0. 85th, 1779 patients), and total failure was equal to 1 ruble. 00, 95% confidence interval (0. 79 to 1. 27 strattera,943 patients). Both mortality and failure did not differ significantly in patients with gram-positive infections, but the comparison were small. Data on other patient subgroups may benefit from treatment antiGP were not available. Glycopeptides not increase the rate of fungal superinfection, and were associated with a reduction in documented Gram-positive superinfections. Stability of colonization was not documented in the studies. .